WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Grasse BIOTECH
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Medical, Diagnostics
PRNewswire | August 08, 2023
Astellas Pharma Inc. and Poseida Therapeutics, Inc. announced a strategic investment to support the advancement of Poseida's commitment to redefining cancer cell therapy. Under the terms of the transaction agreements, Astellas will invest a total of $50 million, including $25 million to acquire 8,333,333 shares of common stock of Poseida (approximately 8.8% of the outstanding common stock of Poseida) at $3.00 per share in a private placement and a one-time $25 million paymen...
Cell and Gene Therapy
Taysha | December 30, 2020
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-driven gene therapy organization focused in on creating and commercializing AAV-based quality treatments for the treatment of monogenic infections of the focal sensory system in both uncommon and huge patient populaces, today reported new increases to its authority group with the arrangements of Greg Gara as Senior Vice President of Manufacturing and Kimberly Lee, D.O., as Senior Vice President of Corporate Communications and Investor Relatio...
Industrial Impact
Amberstone Biosciences, Inc. | January 04, 2022
Amberstone Biosciences an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, today announced the completion of a $12 million Series A financing round. The funding was led by Viva BioInnovator, Co-win Ventures and Sinovation Ventures, with additional support from ChangRong Capital, Lifespan Investments and existing shareholders. Amberstone will use the proceeds from the financing to advance its highly differentiated tumor microenviron...
MedTech, Industry Outlook
Globenewswire | July 18, 2023
Vaxxinity, Inc. a U.S. company pioneering the development of a new class of medicines, announced new data from a Phase 1 clinical trial demonstrating that antibodies derived from its investigational immunotherapeutic for Parkinson’s disease (PD), UB-312, slows seeding of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) of patients with PD as demonstrated using multiple target engagement assays. These data signify that UB-312 has established clear target engagement in PD patient CS...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE